Tripartite motif-containing 3 (TRIM3) enhances ER signaling and confers tamoxifen resistance in breast cancer.
Journal
Oncogenesis
ISSN: 2157-9024
Titre abrégé: Oncogenesis
Pays: United States
ID NLM: 101580004
Informations de publication
Date de publication:
10 Sep 2021
10 Sep 2021
Historique:
received:
10
03
2021
accepted:
23
08
2021
revised:
02
08
2021
entrez:
11
9
2021
pubmed:
12
9
2021
medline:
12
9
2021
Statut:
epublish
Résumé
Tamoxifen resistance remains a clinical problem in estrogen receptor (ER)-positive breast cancer. SUMOylation of ERα enhances ERα-induced transcription activity. Tripartite motif-containing (TRIM) proteins are a new class of SUMO E3 ligases, which regulate the SUMOylation of proteins. However, the precise molecular mechanism and function of TRIM3 in SUMOylation and the response to tamoxifen remain unclear. In the present study, we observed that TRIM3 was dramatically overexpressed in breast cancer, which correlated with tamoxifen resistance. Furthermore, TRIM3 overexpression significantly correlated with poor survival of patients with ER
Identifiants
pubmed: 34508066
doi: 10.1038/s41389-021-00350-x
pii: 10.1038/s41389-021-00350-x
pmc: PMC8433133
doi:
Types de publication
Journal Article
Langues
eng
Pagination
60Subventions
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 81772800
Informations de copyright
© 2021. The Author(s).
Références
J Clin Oncol. 2000 Oct 15;18(20):3471-9
pubmed: 11032587
Breast Cancer Res Treat. 2008 Jan;107(2):195-210
pubmed: 17377839
Scand J Gastroenterol. 2016;51(5):572-82
pubmed: 26691157
Mol Cell. 2003 Apr;11(4):1043-54
pubmed: 12718889
Br J Cancer. 1999 Feb;79(5-6):693-700
pubmed: 10070856
Oncogene. 2013 Aug 29;32(35):4160-8
pubmed: 22986521
Oncogene. 2019 Apr;38(15):2736-2749
pubmed: 30542119
Curr Med Chem. 2015;22(19):2360-74
pubmed: 25882671
Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):16973-8
pubmed: 16287980
Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17284-9
pubmed: 24101509
Methods Mol Biol. 2017;1615:211-219
pubmed: 28667615
Nat Rev Clin Oncol. 2015 Oct;12(10):573-83
pubmed: 26122181
Oncogene. 2005 Apr 14;24(16):2677-83
pubmed: 15735760
Cancer Res. 2016 Apr 15;76(8):2443-52
pubmed: 26893479
Nat Rev Cancer. 2009 Sep;9(9):631-43
pubmed: 19701242
Mol Cell Neurosci. 2005 May;29(1):74-81
pubmed: 15866048
Oncologist. 2006 Jan;11(1):1-8
pubmed: 16401708
Oncogene. 2019 Feb;38(7):1019-1037
pubmed: 30190545
Biochem J. 2014 Mar 15;458(3):537-45
pubmed: 24393003
Cancer Res. 2001 Oct 1;61(19):7025-9
pubmed: 11585728
J Exp Clin Cancer Res. 2018 Jul 21;37(1):162
pubmed: 30031392
Front Endocrinol (Lausanne). 2021 Mar 25;12:599586
pubmed: 33841325
Rev Endocr Metab Disord. 2007 Sep;8(3):229-39
pubmed: 17440819
Oncogene. 2014 Jan 16;33(3):308-15
pubmed: 23318451
Cancer Res. 2014 Aug 15;74(16):4536-48
pubmed: 24947043
Oncogene. 2018 May;37(19):2586-2600
pubmed: 29467493
Mol Endocrinol. 2005 Nov;19(11):2671-84
pubmed: 15961505
Oncogene. 2013 Oct 10;32(41):4883-91
pubmed: 23160374
Clin Cancer Res. 2003 Jun;9(6):1980-9
pubmed: 12796359
J Clin Oncol. 2011 Nov 1;29(31):4160-7
pubmed: 21947828
Oncogene. 2011 Mar 3;30(9):1108-16
pubmed: 20972456
Oncogene. 1995 Jun 15;10(12):2435-46
pubmed: 7784095
Chin J Cancer. 2017 Sep 26;36(1):77
pubmed: 28950898
Nat Rev Cancer. 2011 Oct 07;11(11):792-804
pubmed: 21979307
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Commun. 2018 Oct 9;9(1):4180
pubmed: 30301939
Genomics. 2001 Feb 1;71(3):363-7
pubmed: 11170753
Oncogene. 2003 Oct 20;22(47):7316-39
pubmed: 14576841
Ann Oncol. 2018 Apr 1;29(4):872-880
pubmed: 29360925
Endocr Res. 2004 Nov;30(4):617-21
pubmed: 15666801